Yarrow Bioscience, Inc. 是一家臨床階段的生物科技公司,致力於開發針對自身免疫性甲狀腺疾病的變革性療法。公司總部位於紐約州紐約市。
財務指標
營業收入
2026-09-30
--
2026-06-30
$97K
2026-03-31
$86K
2025-12-31
$130K
營業支出
2026-09-30
$10.74M
2026-06-30
$3.19M
2026-03-31
$3.89M
2025-12-31
$5.34M
淨利潤
2026-09-30
-$9.72M
2026-06-30
-$3M
2026-03-31
-$3.58M
2025-12-31
-$4.83M
淨利潤率
2026-09-30
--
2026-06-30
-3.1K%
2026-03-31
-4.16K%
2025-12-31
-3.72K%
每股收益
2026-09-30
$-0.43
2026-06-30
$-2.14
2026-03-31
$-4.19
2025-12-31
--
息稅折舊攤銷前利潤
2026-09-30
-$9.72M
2026-06-30
-$2.89M
2026-03-31
-$3.57M
2025-12-31
-$4.95M
有效稅率
2026-09-30
--
2026-06-30
--
2026-03-31
--
2025-12-31
-0.08%
項目
2026-09-30
2026-06-30
2026-03-31
2025-12-31
營業收入
--
$97K
$86K
$130K
營業支出
$10.74M
$3.19M
$3.89M
$5.34M
淨利潤
-$9.72M
-$3M
-$3.58M
-$4.83M
淨利潤率
--
-3.1K%
-4.16K%
-3.72K%
每股收益
$-0.43
$-2.14
$-4.19
--
息稅折舊攤銷前利潤
-$9.72M
-$2.89M
-$3.57M
-$4.95M
有效稅率
--
--
--
-0.08%
常見問題
YARW represents a publicly traded equity security available on U.S. markets. The ticker identifies the specific company and its common shares. For accurate details about the underlying business, investors should review the latest YARW company profile and disclosures available on this page and through regulatory filings. Shares can be bought or sold through brokerage accounts, and the stock may be referenced in market data platforms and financial news sources.
The industry classification for YARW is listed in the stock's profile data on this page. Industry context helps investors compare YARW against peers and understand sector-specific risks and opportunities. Because classifications can vary by data provider, reviewing the company's official filings and sector information is useful. The industry also influences how macroeconomic trends and regulatory changes may affect YARW's operations and stock performance over time.
Recent performance for YARW is displayed in the price chart and performance data on this page. Short-term price movements can be driven by company news, broader market trends, and sector developments. For the most current figures, including daily and year-to-date changes, refer to the live data provided here. Historical return comparisons should be made over consistent time frames.
The price-to-earnings ratio for YARW depends on the current share price and the company's trailing or forward earnings, which may not be available for all companies. Check this page for the latest displayed P/E and related valuation metrics. If the figure is not shown, it may be because YARW has no meaningful earnings or the data is not provided. Compare the P/E to industry peers and the company's own history for context.
Earnings reports, including revenue, net income, and earnings per share, are typically available through the company's investor relations site and SEC filings such as 10-Q and 10-K reports. This page may also summarize recent quarterly results and earnings dates for YARW. Reviewing multiple periods helps investors assess trends. Earnings releases often include management commentary and guidance that can influence how the stock reacts.
Risks for YARW include company-specific factors such as competition, execution, and financial leverage, as well as broader market and economic risks. Sector conditions, interest rates, and regulatory changes can also affect performance. Reviewing YARW's risk factors in its latest annual report or 10-K provides detailed disclosure. Concentration, liquidity, and valuation risks may apply, and the stock's price can be volatile.